Skip to content
Evigrade
CriticalClass III antiarrhythmics (Vaughan Williams)×Pharmacokinetic enhancer (booster) for antiretroviral therapy

Updated · Methodology

Mechanism

In the liver, CYP3A4 is the main enzyme that converts amiodarone into its active metabolite desethylamiodarone, and CYP3A4 inhibitors may slow this metabolism and raise amiodarone levels (amiodarone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cobicistat is a strong CYP3A inhibitor used to boost atazanavir or darunavir, and it raises the levels of drugs that CYP3A metabolises (cobicistat SmPC, European Medicines Agency, EMA). The EU cobicistat SmPC places amiodarone among drugs that depend heavily on CYP3A for clearance and whose high levels are linked to serious or life-threatening reactions (cobicistat SmPC, EMA). Amiodarone has a long half-life of 20–100 days, and its interactions can persist for several months after it is stopped (amiodarone SmPC, AEMPS). The effect can also go the other way: amiodarone inhibits CYP3A4 and P-glycoprotein, and CYP3A inhibitors can reduce cobicistat clearance and raise its levels (amiodarone SmPC, AEMPS; cobicistat SmPC, EMA).

Symptoms

According to the cobicistat SmPC, high amiodarone levels are linked to serious or life-threatening adverse reactions (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA). Amiodarone can cause a slow heart rate, conduction disorders (sinoatrial and atrioventricular block), new or worsened arrhythmias, sometimes followed by cardiac arrest, and torsade de pointes (amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Its arrhythmias usually occur when QT-prolonging factors such as drug interactions or electrolyte disorders are present. Overdose has caused sinus bradycardia, heart block, ventricular tachycardia, circulatory failure and liver injury (amiodarone SmPC, AEMPS). A slow pulse or an arrhythmia causes dizziness, palpitations and fainting, while QT prolongation itself causes no symptoms and shows only on an electrocardiogram.

Management

The combination is contraindicated. The EU cobicistat SmPC names amiodarone among contraindicated drugs that depend heavily on CYP3A for clearance and whose high levels are linked to serious or life-threatening reactions (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA). The same contraindication appears in the SmPCs of the combination tablets of cobicistat with darunavir, atazanavir and elvitegravir (SmPCs of these products, EMA). The amiodarone SmPC, for its part, recommends avoiding CYP3A4 inhibitors throughout amiodarone treatment, and the cobicistat SmPC describes cobicistat as a strong CYP3A inhibitor (amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; cobicistat SmPC, EMA). The US cobicistat label is softer and recommends clinical monitoring with amiodarone (cobicistat label, US Food and Drug Administration, FDA). The US amiodarone label advises avoiding CYP450 inhibitors, including certain protease inhibitors (amiodarone FDA label). Amiodarone interactions can persist for several months after it is stopped (amiodarone SmPC, AEMPS, and FDA label), and no document says how long after amiodarone cobicistat can be started. Conditions for amiodarone itself: before starting, record an electrocardiogram (ECG) and measure potassium, correct low potassium and monitor the ECG throughout treatment (amiodarone SmPCs, AEMPS). Also correct low magnesium and calcium before starting (amiodarone FDA label). Stop amiodarone in second- or third-degree atrioventricular block, sinoatrial block or bifascicular block (amiodarone SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Amiodarone

Other interactions with Cobicistat